Myelomatose

Dette dokumentet er basert på det profesjonelle dokumentet Myelomatose. Referanselisten for dette dokumentet vises nedenfor.

1. Rajkumar SV, Kumar S. Myeloma: Diagnosis and Treatment. Mayo Clin Proc 2016;91:101-19. pmid:26763514 PubMed 
2. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, et al.International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538-48. Pmid: 25439696 PubMed 
3. Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. Am Fam Physician. 2017 Mar 15;95(6):373-383A. . pmid:28318212 PubMed 
4. Kreftregisteret. Cancer in Norway 2020. Oslo: Kreftregisteret, 2021. www.kreftregisteret.no.
5. Laubach JP. Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis. UpToDate, last updated Feb 25, 2022. UpToDate 
6. Bianchi G, Anderson KC. Understanding biology to tackle the disease: multiple myeloma from bench to bedside, and back. CA Cancer J Clin. 2014;64(6):422–444.
7. Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undertemined significance. N Engl J Med 2018; 378: 241-9. pmid:29342381 PubMed 
8. Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av maligne blodsykdommer, sist oppdatert 21.12.2021. www.helsedirektoratet.no 
9. Wolf MB, Murray F, Kilk K, Hillengass J, Delorme S, Heiss C, et al. Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease. Eur J Radiol 2014;83(7):1222-30 PubMed 
10. Regelink JC, Minnema MC, Terpos E, et al. Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Br J Haematol. 2013;162(1):50–61.
11. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007;21(3):529-34. PubMed 
12. Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Bisphosphonates in multiple myeloma: an updated network meta‐analysis. Cochrane Database of Systematic Reviews 2017, Issue 12. Art. No.: CD003188. DOI: 10.1002/14651858.CD003188.pub4. DOI 
13. Himelstein AL, Foster JC, Khatcheressian JL et al. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases A Randomized Clinical Trial. JAMA 2017; 317(1): 48-58. pmid:28030702 PubMed 
14. Terpos E, Morgan G, Dimopoulos MA, et al. International Myeloma recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013;31(18):2347–2357.
15. Lyman GH, Bohlke K, Khorana AA, et al.; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654–656. PMID: 25605844. PubMed 
16. Blimark C, Holmberg E, Mellqvist U-H. A population-based study on 9253 multiple myeloma patients. Haematologica 2014. doi:10.3324/haematol.2014.107714 DOI 
17. Greipp PR, San MJ, Durie BG, et al. International staging system for multiple myeloma. J clin Oncol 2005; 23: 3412-20. PubMed 
18. Ludwig H, Durie BGM, Bolejack V, et al. Myeloma in patients under age 50 presents with more favorable features and shows better survival: an analysis of 10,549 patients from the International Myeloma Working Group. Blood 2008; 111: 4039-47. Blood 
19. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106(3): 812-7. pmid:15855274 PubMed